Episode 498: Do You Want a One and Done Cholesterol Infusion? The Long Road Ahead
About this episode
Dr. Joel Kahn discusses a groundbreaking cholesterol treatment and various health topics including cancer screening and Alzheimer's prediction.
Dr. Joel Kahn dives into a groundbreaking Phase 1 trial of Verve 102, a one-time intravenous gene-editing treatment that silences the PCSK9 gene to produce lasting LDL cholesterol reduction. Among 35 participants, the high-dose group saw LDL drop by 62% with mostly mild side effects — promising results, though Phase 2 and 3 trials and 15 years of follow-up still lie ahead. Also covered: updated colorectal cancer screening guidelines now starting at age 45, healthy lifestyle habits cutting mortality risk in cancer survivors by one-third, real-world weight regain data after stopping GLP-1 medications, why your B12 "normal" range may be too low, a blood test that may predict Alzheimer's years in advance, and a longevity preparedness tool from MIT AgeLab. Sponsored by Igennus — visit igennus.com/drkahn for 20% off.
People in this episode
Host: Dr. Joel Kahn
Topics covered
- cholesterol treatment
- gene editing
- cancer screening
- healthy lifestyle
- Alzheimer's prediction
- longevity
Keywords
- cholesterol
- PCSK9
- gene editing
- cancer screening
- B12
- Alzheimer's
- longevity
Sponsors
Igennus
Mentioned in this episode
Organizations: MIT AgeLab
Products: Verve 102
More episodes of Heart Doc VIP with Dr. Joel Kahn
- Episode 505: A Breakthrough in Cholesterol Care With an Oral PCSK9 Inhibitor
- Episode 504: Why Inflammation Matters for Patients with Lp(a)
- Episode 503: Supplements to Reverse Atherosclerosis: Follow-Up to The Proof
- Episode 502: Prozac (Fluoxetine) and Other Drugs That Injure Endothelium
- Episode 501: The Surprising Science of Gratitude and Heart Health
- Episode 500: The Long Path to Building an Integrative Cardiology Practice
Explore listener stats, chart rankings, contacts and more on the Heart Doc VIP with Dr. Joel Kahn podcast page.